{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:32:24Z","timestamp":1791995544753,"version":"4.4.0"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40256-025-00757-6","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T16:07:55Z","timestamp":1756397275000},"page":"21-34","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Cardiovascular Safety of Bruton Tyrosine Kinase Inhibitors: From Ibrutinib to Next-Generation Agents"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6443-4121","authenticated-orcid":false,"given":"Luigi","family":"Spadafora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewelina","family":"Bukowska-Olech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Panichella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Garofalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Cacciatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Sabouret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmarco","family":"Sarto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Simeone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Rocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilio","family":"Lauretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Versaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Biondi","family":"Zoccai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iginio","family":"Colaiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Sciarretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bernardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"issue":"2","key":"757_CR1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.clml.2024.05.019","volume":"25","author":"A Alsouqi","year":"2025","unstructured":"Alsouqi A, Woyach JA. SOHO state of the art updates and next questions|covalent Bruton\u2019s tyrosine kinase inhibitors in chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2025;25(2):89\u201395. https:\/\/doi.org\/10.1016\/j.clml.2024.05.019.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"757_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2025.101268","author":"S Kozarac","year":"2025","unstructured":"Kozarac S, Vukovic V, Fradley M, Antic D. BTKi-induced cardiovascular toxicity in CLL: risk mitigation and management strategies. Blood Rev. 2025. https:\/\/doi.org\/10.1016\/j.blre.2025.101268.","journal-title":"Blood Rev"},{"issue":"10","key":"757_CR3","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1080\/17474086.2024.2391097","volume":"17","author":"A Hatashima","year":"2024","unstructured":"Hatashima A, Shadman M. BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia. Expert Rev Hematol. 2024;17(10):687\u2013703. https:\/\/doi.org\/10.1080\/17474086.2024.2391097.","journal-title":"Expert Rev Hematol"},{"key":"757_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2021.116358","volume":"47","author":"XJ Liu","year":"2021","unstructured":"Liu XJ, Xu L, Pang XJ, et al. Progress in the development of small molecular inhibitors of the Bruton\u2019s tyrosine kinase (BTK) as a promising cancer therapy. Bioorg Med Chem. 2021;47: 116358. https:\/\/doi.org\/10.1016\/j.bmc.2021.116358.","journal-title":"Bioorg Med Chem"},{"issue":"12","key":"757_CR5","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1161\/CIRCRESAHA.121.318259","volume":"128","author":"MR Fleming","year":"2021","unstructured":"Fleming MR, Xiao L, Jackson KD, Beckman JA, Barac A, Moslehi JJ. Vascular impact of cancer therapies: the case of BTK (Bruton tyrosine kinase) inhibitors. Circ Res. 2021;128(12):1973\u201387. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.318259.","journal-title":"Circ Res"},{"issue":"6","key":"757_CR6","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/PPO.0000000000000412","volume":"25","author":"JA Burger","year":"2019","unstructured":"Burger JA. Bruton tyrosine kinase inhibitors: present and future. Cancer J. 2019;25(6):386\u201393. https:\/\/doi.org\/10.1097\/PPO.0000000000000412.","journal-title":"Cancer J"},{"issue":"8","key":"757_CR7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11864-020-00764-6","volume":"21","author":"R Pineda-Gayoso","year":"2020","unstructured":"Pineda-Gayoso R, Alomar M, Lee DH, Fradley MG. cardiovascular toxicities of Bruton\u2019s tyrosine kinase inhibitors. Curr Treat Options Oncol. 2020;21(8):67. https:\/\/doi.org\/10.1007\/s11864-020-00764-6.","journal-title":"Curr Treat Options Oncol"},{"issue":"18","key":"757_CR8","doi-asserted-by":"publisher","first-page":"5516","DOI":"10.1182\/bloodadvances.2022007938","volume":"6","author":"FT Awan","year":"2022","unstructured":"Awan FT, Addison D, Alfraih F, et al. International consensus statement on the management of cardiovascular risk of Bruton\u2019s tyrosine kinase inhibitors in CLL. Blood Adv. 2022;6(18):5516\u201325. https:\/\/doi.org\/10.1182\/bloodadvances.2022007938.","journal-title":"Blood Adv"},{"issue":"10","key":"757_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s11912-021-01102-1","volume":"23","author":"M Sestier","year":"2021","unstructured":"Sestier M, Hillis C, Fraser G, Leong D. Bruton\u2019s tyrosine kinase inhibitors and cardiotoxicity: more than just atrial fibrillation. Curr Oncol Rep. 2021;23(10):113. https:\/\/doi.org\/10.1007\/s11912-021-01102-1.","journal-title":"Curr Oncol Rep"},{"issue":"9","key":"757_CR10","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s11886-023-01916-4","volume":"25","author":"N Aghel","year":"2023","unstructured":"Aghel N, Baro Vila RC, Lui M, Hillis C, Leong DP. Diagnosis and management of cardiovascular effects of Bruton\u2019s tyrosine kinase inhibitors. Curr Cardiol Rep. 2023;25(9):941\u201358. https:\/\/doi.org\/10.1007\/s11886-023-01916-4.","journal-title":"Curr Cardiol Rep"},{"issue":"5","key":"757_CR11","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.jaccao.2023.09.002","volume":"5","author":"C Quartermaine","year":"2023","unstructured":"Quartermaine C, Ghazi SM, Yasin A, et al. Cardiovascular toxicities of BTK inhibitors in chronic lymphocytic leukemia: JACC: cardiooncology state-of-the-art review. JACC CardioOncol. 2023;5(5):570\u201390. https:\/\/doi.org\/10.1016\/j.jaccao.2023.09.002.","journal-title":"JACC CardioOncol"},{"issue":"14","key":"757_CR12","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1002\/cncr.34787","volume":"129","author":"MJ Gordon","year":"2023","unstructured":"Gordon MJ, Jones JE, George B, et al. Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: focus on hypertension and cardiovascular toxicity. Cancer. 2023;129(14):2192\u2013200. https:\/\/doi.org\/10.1002\/cncr.34787.","journal-title":"Cancer"},{"issue":"2","key":"757_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211228","volume":"14","author":"D Caldeira","year":"2019","unstructured":"Caldeira D, Alves D, Costa J, Ferreira JJ, Pinto FJ. Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis. PLoS ONE. 2019;14(2): e0211228. https:\/\/doi.org\/10.1371\/journal.pone.0211228.","journal-title":"PLoS ONE"},{"key":"757_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.630942","volume":"9","author":"HY Estupinan","year":"2021","unstructured":"Estupinan HY, Berglof A, Zain R, Smith CIE. Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects. Front Cell Dev Biol. 2021;9: 630942. https:\/\/doi.org\/10.3389\/fcell.2021.630942.","journal-title":"Front Cell Dev Biol"},{"key":"757_CR15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.critrevonc.2019.02.001","volume":"136","author":"S Paydas","year":"2019","unstructured":"Paydas S. Management of adverse effects\/toxicity of ibrutinib. Crit Rev Oncol Hematol. 2019;136:56\u201363. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.02.001.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"19","key":"757_CR16","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood-2018-08-870238","volume":"133","author":"JC Byrd","year":"2019","unstructured":"Byrd JC, Hillmen P, O\u2019Brien S, et al. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood. 2019;133(19):2031\u201342. https:\/\/doi.org\/10.1182\/blood-2018-08-870238.","journal-title":"Blood"},{"issue":"11","key":"757_CR17","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","volume":"6","author":"PM Barr","year":"2022","unstructured":"Barr PM, Owen C, Robak T, et al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022;6(11):3440\u201350. https:\/\/doi.org\/10.1182\/bloodadvances.2021006434.","journal-title":"Blood Adv"},{"issue":"4","key":"757_CR18","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.24.00975","volume":"43","author":"P Langerbeins","year":"2025","unstructured":"Langerbeins P, Robrecht S, Nieper P, et al. Ibrutinib in early-stage chronic lymphocytic leukemia: the randomized, placebo-controlled, double-blind, phase III CLL12 trial. J Clin Oncol. 2025;43(4):392\u2013402. https:\/\/doi.org\/10.1200\/JCO.24.00975.","journal-title":"J Clin Oncol"},{"issue":"2","key":"757_CR19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s40265-014-0178-8","volume":"74","author":"F Cameron","year":"2014","unstructured":"Cameron F, Sanford M. Ibrutinib: first global approval. Drugs. 2014;74(2):263\u201371. https:\/\/doi.org\/10.1007\/s40265-014-0178-8.","journal-title":"Drugs"},{"issue":"1","key":"757_CR20","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1182\/hematology.2020000118","volume":"2020","author":"A Lipsky","year":"2020","unstructured":"Lipsky A, Lamanna N. Managing toxicities of Bruton tyrosine kinase inhibitors. Hematol Am Soc Hematol Educ Program. 2020;2020(1):336\u201345. https:\/\/doi.org\/10.1182\/hematology.2020000118.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"1","key":"757_CR21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13045-016-0313-y","volume":"9","author":"J Wu","year":"2016","unstructured":"Wu J, Liu C, Tsui ST, Liu D. Second-generation inhibitors of Bruton tyrosine kinase. J Hematol Oncol. 2016;9(1):80. https:\/\/doi.org\/10.1186\/s13045-016-0313-y.","journal-title":"J Hematol Oncol"},{"key":"757_CR22","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.2147\/DDDT.S377697","volume":"16","author":"R Dong","year":"2022","unstructured":"Dong R, Yan Y, Zeng X, Lin N, Tan B. Ibrutinib-associated cardiotoxicity: from the pharmaceutical to the clinical. Drug Des Dev Ther. 2022;16:3225\u201339. https:\/\/doi.org\/10.2147\/DDDT.S377697.","journal-title":"Drug Des Dev Ther"},{"issue":"12","key":"757_CR23","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.jacep.2018.06.004","volume":"4","author":"S Ganatra","year":"2018","unstructured":"Ganatra S, Sharma A, Shah S, et al. Ibrutinib-associated atrial fibrillation. JACC Clin Electrophysiol. 2018;4(12):1491\u2013500. https:\/\/doi.org\/10.1016\/j.jacep.2018.06.004.","journal-title":"JACC Clin Electrophysiol"},{"key":"757_CR24","doi-asserted-by":"publisher","first-page":"0509","DOI":"10.34133\/research.0509","volume":"7","author":"Y Li","year":"2024","unstructured":"Li Y, Liu X, Lin R, et al. Ibrutinib promotes atrial fibrillation by disrupting A-kinase anchoring protein 1-mediated mitochondrial quality surveillance in cardiomyocytes. Research (Wash D C). 2024;7:0509. https:\/\/doi.org\/10.34133\/research.0509.","journal-title":"Research (Wash D C)"},{"issue":"25","key":"757_CR25","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","volume":"124","author":"JR McMullen","year":"2014","unstructured":"McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ, Tam CS. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014;124(25):3829\u201330. https:\/\/doi.org\/10.1182\/blood-2014-10-604272.","journal-title":"Blood"},{"key":"757_CR26","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0000000000000558","author":"KI Nugent","year":"2025","unstructured":"Nugent KI, Huang L, Patel JN, Hertz DL. Pharmacogenetic associations of GATA4 and KCNQ1 with ibrutinib cardiovascular toxicity. Pharmacogenet Genom. 2025. https:\/\/doi.org\/10.1097\/FPC.0000000000000558.","journal-title":"Pharmacogenet Genom"},{"issue":"2","key":"757_CR27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4274\/tjh.galenos.2024.2024.0045","volume":"41","author":"I Koyuncu","year":"2024","unstructured":"Koyuncu I, Koyuncu B, Ugur MC, et al. A new scoring system for the evaluation of ibrutinib-associated arrhythmias in chronic lymphocytic leukemia: the ACEF score. Turk J Haematol. 2024;41(2):91\u20136. https:\/\/doi.org\/10.4274\/tjh.galenos.2024.2024.0045.","journal-title":"Turk J Haematol"},{"issue":"1","key":"757_CR28","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s40265-017-0852-8","volume":"78","author":"A Markham","year":"2018","unstructured":"Markham A, Dhillon S. Acalabrutinib: first global approval. Drugs. 2018;78(1):139\u201345. https:\/\/doi.org\/10.1007\/s40265-017-0852-8.","journal-title":"Drugs"},{"issue":"12","key":"757_CR29","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000801","volume":"6","author":"P Ghia","year":"2022","unstructured":"Ghia P, Pluta A, Wach M, et al. Acalabrutinib versus investigator\u2019s choice in relapsed\/refractory chronic lymphocytic leukemia: final ASCEND trial results. Hemasphere. 2022;6(12): e801. https:\/\/doi.org\/10.1097\/HS9.0000000000000801.","journal-title":"Hemasphere"},{"issue":"31","key":"757_CR30","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/JCO.21.01210","volume":"39","author":"JC Byrd","year":"2021","unstructured":"Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39(31):3441\u201352. https:\/\/doi.org\/10.1200\/JCO.21.01210.","journal-title":"J Clin Oncol"},{"issue":"8","key":"757_CR31","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1182\/blood.2022018818","volume":"142","author":"JF Seymour","year":"2023","unstructured":"Seymour JF, Byrd JC, Ghia P, et al. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the elevate-rr trial. Blood. 2023;142(8):687\u201399. https:\/\/doi.org\/10.1182\/blood.2022018818.","journal-title":"Blood"},{"issue":"10232","key":"757_CR32","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","volume":"395","author":"JP Sharman","year":"2020","unstructured":"Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395(10232):1278\u201391. https:\/\/doi.org\/10.1016\/S0140-6736(20)30262-2.","journal-title":"Lancet"},{"issue":"10121","key":"757_CR33","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","volume":"391","author":"M Wang","year":"2018","unstructured":"Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391(10121):659\u201367. https:\/\/doi.org\/10.1016\/S0140-6736(17)33108-2.","journal-title":"Lancet"},{"issue":"24","key":"757_CR34","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1182\/blood.2019852368","volume":"133","author":"TE Witzig","year":"2019","unstructured":"Witzig TE, Inwards D. Acalabrutinib for mantle cell lymphoma. Blood. 2019;133(24):2570\u20134. https:\/\/doi.org\/10.1182\/blood.2019852368.","journal-title":"Blood"},{"key":"757_CR35","doi-asserted-by":"publisher","first-page":"6573","DOI":"10.2147\/OTT.S238832","volume":"13","author":"Y Sawalha","year":"2020","unstructured":"Sawalha Y, Bond DA, Alinari L. Evaluating the therapeutic potential of zanubrutinib in the treatment of relapsed\/refractory mantle cell lymphoma: evidence to date. Onco Targets Ther. 2020;13:6573\u201381. https:\/\/doi.org\/10.2147\/OTT.S238832.","journal-title":"Onco Targets Ther"},{"issue":"17","key":"757_CR36","doi-asserted-by":"publisher","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","volume":"62","author":"Y Guo","year":"2019","unstructured":"Guo Y, Liu Y, Hu N, et al. Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton\u2019s tyrosine kinase. J Med Chem. 2019;62(17):7923\u201340. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b00687.","journal-title":"J Med Chem"},{"issue":"1","key":"757_CR37","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40265-019-01252-4","volume":"80","author":"YY Syed","year":"2020","unstructured":"Syed YY. Zanubrutinib: first approval. Drugs. 2020;80(1):91\u20137. https:\/\/doi.org\/10.1007\/s40265-019-01252-4.","journal-title":"Drugs"},{"issue":"1","key":"757_CR38","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41408-023-00902-x","volume":"13","author":"CS Tam","year":"2023","unstructured":"Tam CS, Munoz JL, Seymour JF, Opat S. Zanubrutinib: past, present, and future. Blood Cancer J. 2023;13(1):141. https:\/\/doi.org\/10.1038\/s41408-023-00902-x.","journal-title":"Blood Cancer J"},{"issue":"4","key":"757_CR39","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa2211582","volume":"388","author":"JR Brown","year":"2023","unstructured":"Brown JR, Eichhorst B, Hillmen P, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388(4):319\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2211582.","journal-title":"N Engl J Med"},{"issue":"18","key":"757_CR40","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood.2020006844","volume":"136","author":"CS Tam","year":"2020","unstructured":"Tam CS, Opat S, D\u2019Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study. Blood. 2020;136(18):2038\u201350. https:\/\/doi.org\/10.1182\/blood.2020006844.","journal-title":"Blood"},{"issue":"11","key":"757_CR41","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1080\/03007995.2023.2262378","volume":"39","author":"CS Tam","year":"2023","unstructured":"Tam CS, Lamanna N, O\u2019Brien SM, et al. Health-related quality of life outcomes associated with zanubrutinib versus ibrutinib monotherapy in patients with relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from the ALPINE trial. Curr Med Res Opin. 2023;39(11):1497\u2013503. https:\/\/doi.org\/10.1080\/03007995.2023.2262378.","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"757_CR42","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1182\/bloodadvances.2023011641","volume":"8","author":"JJ Moslehi","year":"2024","unstructured":"Moslehi JJ, Furman RR, Tam CS, et al. Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib. Blood Adv. 2024;8(10):2478\u201390. https:\/\/doi.org\/10.1182\/bloodadvances.2023011641.","journal-title":"Blood Adv"},{"key":"757_CR43","doi-asserted-by":"publisher","first-page":"204062072210939","DOI":"10.1177\/20406207221093980","volume":"13","author":"J Munoz","year":"2022","unstructured":"Munoz J, Wang Y, Jain P, Wang M. Zanubrutinib in lymphoproliferative disorders: a comprehensive review. Ther Adv Hematol. 2022;13:20406207221093980. https:\/\/doi.org\/10.1177\/20406207221093980.","journal-title":"Ther Adv Hematol"},{"key":"757_CR44","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2147\/BLCTT.S426588","volume":"13","author":"N Alsuhebany","year":"2023","unstructured":"Alsuhebany N, Pan C, Holovac E, Do B, McBride A. Zanubrutinib in mantle cell lymphoma management: a comprehensive review. Blood Lymphat Cancer. 2023;13:67\u201376. https:\/\/doi.org\/10.2147\/BLCTT.S426588.","journal-title":"Blood Lymphat Cancer"},{"issue":"21","key":"757_CR45","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1182\/blood.2021014162","volume":"139","author":"Y Song","year":"2022","unstructured":"Song Y, Zhou K, Zou D, et al. Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood. 2022;139(21):3148\u201358. https:\/\/doi.org\/10.1182\/blood.2021014162.","journal-title":"Blood"},{"issue":"1","key":"757_CR46","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdae037","volume":"6","author":"H Yonezawa","year":"2024","unstructured":"Yonezawa H, Narita Y, Nagane M, et al. Three-year follow-up analysis of phase 1\/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma. Neurooncol Adv. 2024;6(1): vdae037. https:\/\/doi.org\/10.1093\/noajnl\/vdae037.","journal-title":"Neurooncol Adv"},{"issue":"8","key":"757_CR47","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s40265-020-01318-8","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon S. Tirabrutinib: first approval. Drugs. 2020;80(8):835\u201340. https:\/\/doi.org\/10.1007\/s40265-020-01318-8.","journal-title":"Drugs"},{"issue":"4","key":"757_CR48","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/jha2.966","volume":"5","author":"ANM Alqahtani","year":"2024","unstructured":"Alqahtani ANM, Jayne S, Ahearne MJ, et al. Monitoring of molecular responses to tirabrutinib in a cohort of exceptional responders with relapsed\/refractory mantle cell lymphoma. EJHaem. 2024;5(4):896\u20139. https:\/\/doi.org\/10.1002\/jha2.966.","journal-title":"EJHaem"},{"issue":"4","key":"757_CR49","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s40265-021-01482-5","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S. Orelabrutinib: first approval. Drugs. 2021;81(4):503\u20137. https:\/\/doi.org\/10.1007\/s40265-021-01482-5.","journal-title":"Drugs"},{"issue":"3","key":"757_CR50","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/bjh.19146","volume":"204","author":"H Liu","year":"2024","unstructured":"Liu H, Ding K, Zhang W, et al. A pilot study of orelabrutinib treatment in three cases of refractory\/relapsed autoimmune haemolytic anaemia\/Evans syndrome. Br J Haematol. 2024;204(3):1082\u20135. https:\/\/doi.org\/10.1111\/bjh.19146.","journal-title":"Br J Haematol"},{"issue":"3","key":"757_CR51","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1111\/bjh.19596","volume":"205","author":"YH Gao","year":"2024","unstructured":"Gao YH, Duan MH, Li J, Zhang L. Successful treatment of relapsed idiopathic multicentric Castleman disease-idiopathic plasmacytic lymphadenopathy with orelabrutinib monotherapy: a case report. Br J Haematol. 2024;205(3):1208\u201311. https:\/\/doi.org\/10.1111\/bjh.19596.","journal-title":"Br J Haematol"},{"issue":"8","key":"757_CR52","doi-asserted-by":"publisher","first-page":"4609","DOI":"10.1007\/s10238-023-01231-w","volume":"23","author":"R Wei","year":"2023","unstructured":"Wei R, Wu Y, Jiang S, et al. Efficacy and safety of orelabrutinib-based regimens in diffuse large B-cell lymphoma: a single-center retrospective analysis. Clin Exp Med. 2023;23(8):4609\u201321. https:\/\/doi.org\/10.1007\/s10238-023-01231-w.","journal-title":"Clin Exp Med"},{"key":"757_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051504","author":"AM Frustaci","year":"2023","unstructured":"Frustaci AM, Deodato M, Zamprogna G, Cairoli R, Montillo M, Tedeschi A. Next generation BTK inhibitors in CLL: evolving challenges and new opportunities. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15051504.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"757_CR54","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1158\/1078-0432.CCR-23-0409","volume":"30","author":"V Nawaratne","year":"2024","unstructured":"Nawaratne V, Sondhi AK, Abdel-Wahab O, Taylor J. New means and challenges in the targeting of BTK. Clin Cancer Res. 2024;30(11):2333\u201341. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0409.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"757_CR55","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1182\/bloodadvances.2023012221","volume":"8","author":"C Tam","year":"2024","unstructured":"Tam C, Thompson PA. BTK inhibitors in CLL: second-generation drugs and beyond. Blood Adv. 2024;8(9):2300\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2023012221.","journal-title":"Blood Adv"},{"issue":"1","key":"757_CR56","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3324\/haematol.2021.279158","volume":"107","author":"B Aslan","year":"2022","unstructured":"Aslan B, Hubner SE, Fox JA, et al. Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase. Haematologica. 2022;107(1):292\u20137. https:\/\/doi.org\/10.3324\/haematol.2021.279158.","journal-title":"Haematologica"},{"issue":"4","key":"757_CR57","doi-asserted-by":"publisher","first-page":"984","DOI":"10.3324\/haematol.2021.280061","volume":"107","author":"JN Allan","year":"2022","unstructured":"Allan JN, Pinilla-Ibarz J, Gladstone DE, et al. Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton\u2019s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies. Haematologica. 2022;107(4):984\u20137. https:\/\/doi.org\/10.3324\/haematol.2021.280061.","journal-title":"Haematologica"},{"issue":"6","key":"757_CR58","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1182\/blood.2021011516","volume":"139","author":"BMC Jebaraj","year":"2022","unstructured":"Jebaraj BMC, Muller A, Dheenadayalan RP, et al. Evaluation of vecabrutinib as a model for noncovalent BTK\/ITK inhibition for treatment of chronic lymphocytic leukemia. Blood. 2022;139(6):859\u201375. https:\/\/doi.org\/10.1182\/blood.2021011516.","journal-title":"Blood"},{"issue":"1","key":"757_CR59","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1177\/10781552231216886","volume":"30","author":"DD Davis","year":"2024","unstructured":"Davis DD, Ohana Z, Pham HM. Pirtobrutinib: a novel non-covalent BTK inhibitor for the treatment of adults with relapsed\/refractory mantle cell lymphoma. J Oncol Pharm Pract. 2024;30(1):182\u20138. https:\/\/doi.org\/10.1177\/10781552231216886.","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"757_CR60","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2300696","volume":"389","author":"AR Mato","year":"2023","unstructured":"Mato AR, Woyach JA, Brown JR, et al. Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. N Engl J Med. 2023;389(1):33\u201344. https:\/\/doi.org\/10.1056\/NEJMoa2300696.","journal-title":"N Engl J Med"},{"issue":"6","key":"757_CR61","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40265-023-01860-1","volume":"83","author":"SJ Keam","year":"2023","unstructured":"Keam SJ. Pirtobrutinib: first approval. Drugs. 2023;83(6):547\u201353. https:\/\/doi.org\/10.1007\/s40265-023-01860-1.","journal-title":"Drugs"},{"issue":"9","key":"757_CR62","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1182\/bloodadvances.2022008447","volume":"7","author":"A Naeem","year":"2023","unstructured":"Naeem A, Utro F, Wang Q, et al. Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance. Blood Adv. 2023;7(9):1929\u201343. https:\/\/doi.org\/10.1182\/bloodadvances.2022008447.","journal-title":"Blood Adv"},{"issue":"1","key":"757_CR63","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1182\/blood.2022018674","volume":"142","author":"EB Gomez","year":"2023","unstructured":"Gomez EB, Ebata K, Randeria HS, et al. Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor. Blood. 2023;142(1):62\u201372. https:\/\/doi.org\/10.1182\/blood.2022018674.","journal-title":"Blood"},{"issue":"24","key":"757_CR64","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1200\/JCO.23.00562","volume":"41","author":"ML Wang","year":"2023","unstructured":"Wang ML, Jurczak W, Zinzani PL, et al. Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma. J Clin Oncol. 2023;41(24):3988\u201397. https:\/\/doi.org\/10.1200\/JCO.23.00562.","journal-title":"J Clin Oncol"},{"issue":"10277","key":"757_CR65","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","volume":"397","author":"AR Mato","year":"2021","unstructured":"Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study. Lancet. 2021;397(10277):892\u2013901. https:\/\/doi.org\/10.1016\/S0140-6736(21)00224-5.","journal-title":"Lancet"},{"key":"757_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143648","author":"S Montoya","year":"2023","unstructured":"Montoya S, Thompson MC. Non-covalent Bruton\u2019s tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15143648.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"757_CR67","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13045-022-01386-1","volume":"15","author":"EM Muhowski","year":"2022","unstructured":"Muhowski EM, Ravikrishnan J, Gordon B, et al. Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia. J Hematol Oncol. 2022;15(1):166. https:\/\/doi.org\/10.1186\/s13045-022-01386-1.","journal-title":"J Hematol Oncol"},{"key":"757_CR68","doi-asserted-by":"publisher","first-page":"355","DOI":"10.18632\/oncotarget.28589","volume":"15","author":"JN Patel","year":"2024","unstructured":"Patel JN, Singh J, Ghosh N. Bruton\u2019s tyrosine kinase inhibitor-related cardiotoxicity: the quest for predictive biomarkers and improved risk stratification. Oncotarget. 2024;15:355\u20139. https:\/\/doi.org\/10.18632\/oncotarget.28589.","journal-title":"Oncotarget"},{"issue":"1","key":"757_CR69","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40959-024-00237-x","volume":"10","author":"S Vallabhaneni","year":"2024","unstructured":"Vallabhaneni S, Adusumalli S, Wu J, Groeneveld PW, Gerson J, O\u2019Quinn RP. Cardiotoxicity from bruton tyrosine kinase inhibitors (BTKi)\u2014an analysis of an administrative health claims database. Cardiooncology. 2024;10(1):33. https:\/\/doi.org\/10.1186\/s40959-024-00237-x.","journal-title":"Cardiooncology"},{"issue":"7","key":"757_CR70","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1080\/10428194.2017.1375110","volume":"59","author":"CPS Tang","year":"2018","unstructured":"Tang CPS, McMullen J, Tam C. Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors. Leuk Lymphoma. 2018;59(7):1554\u201364. https:\/\/doi.org\/10.1080\/10428194.2017.1375110.","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"757_CR71","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1182\/blood.2019000840","volume":"134","author":"T Dickerson","year":"2019","unstructured":"Dickerson T, Wiczer T, Waller A, et al. Hypertension and incident cardiovascular events following ibrutinib initiation. Blood. 2019;134(22):1919\u201328. https:\/\/doi.org\/10.1182\/blood.2019000840.","journal-title":"Blood"},{"issue":"25","key":"757_CR72","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1161\/CIRCULATIONAHA.120.049210","volume":"142","author":"L Xiao","year":"2020","unstructured":"Xiao L, Salem JE, Clauss S, et al. Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal Src kinase. Circulation. 2020;142(25):2443\u201355. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.049210.","journal-title":"Circulation"},{"issue":"4","key":"757_CR73","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00280-020-04137-6","volume":"86","author":"KM Fancher","year":"2020","unstructured":"Fancher KM, Pappacena JJ. Drug interactions with Bruton\u2019s tyrosine kinase inhibitors: clinical implications and management. Cancer Chemother Pharmacol. 2020;86(4):507\u201315. https:\/\/doi.org\/10.1007\/s00280-020-04137-6.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"22","key":"757_CR74","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1093\/eurheartj\/ehae161","volume":"45","author":"I Fabiani","year":"2024","unstructured":"Fabiani I, Chianca M, Aimo A, et al. Use of new and emerging cancer drugs: what the cardiologist needs to know. Eur Heart J. 2024;45(22):1971\u201387. https:\/\/doi.org\/10.1093\/eurheartj\/ehae161.","journal-title":"Eur Heart J"},{"issue":"1","key":"757_CR75","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1182\/blood-2016-05-712828","volume":"128","author":"DP Leong","year":"2016","unstructured":"Leong DP, Caron F, Hillis C, et al. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood. 2016;128(1):138\u201340. https:\/\/doi.org\/10.1182\/blood-2016-05-712828.","journal-title":"Blood"},{"issue":"1","key":"757_CR76","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00277-020-04094-3","volume":"100","author":"WJ Archibald","year":"2021","unstructured":"Archibald WJ, Rabe KG, Kabat BF, et al. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes. Ann Hematol. 2021;100(1):143\u201355. https:\/\/doi.org\/10.1007\/s00277-020-04094-3.","journal-title":"Ann Hematol"},{"issue":"7","key":"757_CR77","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1080\/10428194.2016.1257795","volume":"58","author":"TD Shanafelt","year":"2017","unstructured":"Shanafelt TD, Parikh SA, Noseworthy PA, et al. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2017;58(7):1630\u20139. https:\/\/doi.org\/10.1080\/10428194.2016.1257795.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"757_CR78","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/hon.2655","volume":"37","author":"A Visentin","year":"2019","unstructured":"Visentin A, Deodato M, Mauro FR, et al. A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia. Hematol Oncol. 2019;37(4):508\u201312. https:\/\/doi.org\/10.1002\/hon.2655.","journal-title":"Hematol Oncol"},{"issue":"41","key":"757_CR79","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, Lopez-Fernandez T, Couch LS, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229\u2013361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244.","journal-title":"Eur Heart J"},{"issue":"1","key":"757_CR80","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-022-01302-7","volume":"15","author":"ST Chen","year":"2022","unstructured":"Chen ST, Azali L, Rosen L, et al. Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation. J Hematol Oncol. 2022;15(1):92. https:\/\/doi.org\/10.1186\/s13045-022-01302-7.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"757_CR81","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1097\/MJT.0000000000001463","volume":"29","author":"DC Ciuculete","year":"2022","unstructured":"Ciuculete DC, Popescu RA, Georgescu GD, Dan GA. Evaluation of ibrutinib cardiotoxicity by comparative use of speckle-tracking technique and biomarkers. Am J Ther. 2022;29(1):e50\u20135. https:\/\/doi.org\/10.1097\/MJT.0000000000001463.","journal-title":"Am J Ther"},{"issue":"5","key":"757_CR82","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000564","volume":"5","author":"TA Mulder","year":"2021","unstructured":"Mulder TA, Pena-Perez L, Berglof A, et al. Ibrutinib has time-dependent on- and off-target effects on plasma biomarkers and immune cells in chronic lymphocytic leukemia. Hemasphere. 2021;5(5): e564. https:\/\/doi.org\/10.1097\/HS9.0000000000000564.","journal-title":"Hemasphere"},{"issue":"23","key":"757_CR83","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1158\/1078-0432.CCR-23-0421","volume":"29","author":"IS Hamadeh","year":"2023","unstructured":"Hamadeh IS, Patel JN, Jacobs R, et al. Genetic predictors of ibrutinib-related cardiovascular side effects in patients with chronic lymphocytic leukemia. Clin Cancer Res. 2023;29(23):4941\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0421.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"757_CR84","doi-asserted-by":"publisher","first-page":"107327482093180","DOI":"10.1177\/1073274820931808","volume":"27","author":"MG Fradley","year":"2020","unstructured":"Fradley MG, Welter-Frost A, Gliksman M, et al. Electrocardiographic changes associated with ibrutinib exposure. Cancer Control. 2020;27(1):1073274820931808. https:\/\/doi.org\/10.1177\/1073274820931808.","journal-title":"Cancer Control"},{"issue":"6","key":"757_CR85","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s00280-017-3471-x","volume":"80","author":"J de Jong","year":"2017","unstructured":"de Jong J, Hellemans P, Jiao JJ, et al. Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study. Cancer Chemother Pharmacol. 2017;80(6):1227\u201337. https:\/\/doi.org\/10.1007\/s00280-017-3471-x.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"757_CR86","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1038\/s41375-024-02334-3","volume":"38","author":"JA Gambril","year":"2024","unstructured":"Gambril JA, Ghazi SM, Sansoterra S, et al. Atrial fibrillation burden and clinical outcomes following BTK inhibitor initiation. Leukemia. 2024;38(10):2141\u20139. https:\/\/doi.org\/10.1038\/s41375-024-02334-3.","journal-title":"Leukemia"},{"issue":"2","key":"757_CR87","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jaccao.2024.02.006","volume":"6","author":"G Christopoulos","year":"2024","unstructured":"Christopoulos G, Attia ZI, Achenbach SJ, et al. Artificial intelligence electrocardiography to predict atrial fibrillation in patients with chronic lymphocytic leukemia. JACC CardioOncol. 2024;6(2):251\u201363. https:\/\/doi.org\/10.1016\/j.jaccao.2024.02.006.","journal-title":"JACC CardioOncol"},{"issue":"1","key":"757_CR88","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13045-018-0626-0","volume":"11","author":"G Reda","year":"2018","unstructured":"Reda G, Fattizzo B, Cassin R, et al. Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study. J Hematol Oncol. 2018;11(1):79. https:\/\/doi.org\/10.1186\/s13045-018-0626-0.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"757_CR89","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1001\/jamaoncol.2022.6869","volume":"9","author":"B Buck","year":"2023","unstructured":"Buck B, Chum AP, Patel M, et al. Cardiovascular magnetic resonance imaging in patients with ibrutinib-associated cardiotoxicity. JAMA Oncol. 2023;9(4):552\u20135. https:\/\/doi.org\/10.1001\/jamaoncol.2022.6869.","journal-title":"JAMA Oncol"},{"issue":"10","key":"757_CR90","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.clml.2018.06.016","volume":"18","author":"S O\u2019Brien","year":"2018","unstructured":"O\u2019Brien S, Hillmen P, Coutre S, et al. Safety analysis of four randomized controlled studies of ibrutinib in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma or mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2018;18(10):648\u201357. https:\/\/doi.org\/10.1016\/j.clml.2018.06.016.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"757_CR91","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/HJH.0000000000003937","volume":"43","author":"L Ysebaert","year":"2025","unstructured":"Ysebaert L, Protin C, Oberic L, et al. Ibrutinib pharmacokinetics in B-lymphoproliferative disorders discloses exposure-related incidence of hypertension. J Hypertens. 2025;43(3):521\u20138. https:\/\/doi.org\/10.1097\/HJH.0000000000003937.","journal-title":"J Hypertens"},{"issue":"9","key":"757_CR92","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1182\/bloodadvances.2023011569","volume":"8","author":"L Samples","year":"2024","unstructured":"Samples L, Voutsinas J, Fakhri B, et al. Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective study. Blood Adv. 2024;8(9):2085\u201393. https:\/\/doi.org\/10.1182\/bloodadvances.2023011569.","journal-title":"Blood Adv"},{"issue":"11","key":"757_CR93","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1182\/bloodadvances.2023012142","volume":"8","author":"AS Kittai","year":"2024","unstructured":"Kittai AS, Allan JN, James D, et al. An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL. Blood Adv. 2024;8(11):2861\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2023012142.","journal-title":"Blood Adv"},{"issue":"38","key":"757_CR94","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912\u20134018. https:\/\/doi.org\/10.1093\/eurheartj\/ehae178.","journal-title":"Eur Heart J"},{"issue":"2","key":"757_CR95","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41440-021-00827-7","volume":"45","author":"K Katsurada","year":"2022","unstructured":"Katsurada K, Shinohara K, Aoki J, Nanto S, Kario K. Renal denervation: basic and clinical evidence. Hypertens Res. 2022;45(2):198\u2013209. https:\/\/doi.org\/10.1038\/s41440-021-00827-7.","journal-title":"Hypertens Res"},{"issue":"18","key":"757_CR96","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","volume":"129","author":"BL Lampson","year":"2017","unstructured":"Lampson BL, Yu L, Glynn RJ, et al. Ventricular arrhythmias and sudden death in patients taking ibrutinib. Blood. 2017;129(18):2581\u20134. https:\/\/doi.org\/10.1182\/blood-2016-10-742437.","journal-title":"Blood"},{"issue":"5","key":"757_CR97","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/jth.13651","volume":"15","author":"JJ Shatzel","year":"2017","unstructured":"Shatzel JJ, Olson SR, Tao DL, McCarty OJT, Danilov AV, DeLoughery TG. Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. J Thromb Haemost. 2017;15(5):835\u201347. https:\/\/doi.org\/10.1111\/jth.13651.","journal-title":"J Thromb Haemost"},{"issue":"10","key":"757_CR98","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1111\/jth.14943","volume":"18","author":"EA Dmitrieva","year":"2020","unstructured":"Dmitrieva EA, Nikitin EA, Ignatova AA, et al. Platelet function and bleeding in chronic lymphocytic leukemia and mantle cell lymphoma patients on ibrutinib. J Thromb Haemost. 2020;18(10):2672\u201384. https:\/\/doi.org\/10.1111\/jth.14943.","journal-title":"J Thromb Haemost"},{"issue":"7","key":"757_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.04.001","volume":"19","author":"M Lucijanic","year":"2019","unstructured":"Lucijanic M, Skelin M. Platelet counts and risk of major bleeding with ibrutinib. Clin Lymphoma Myeloma Leuk. 2019;19(7): e399. https:\/\/doi.org\/10.1016\/j.clml.2019.04.001.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"757_CR100","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","volume":"23","author":"J Steffel","year":"2021","unstructured":"Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612\u201376. https:\/\/doi.org\/10.1093\/europace\/euab065.","journal-title":"Europace"},{"issue":"3","key":"757_CR101","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s11899-020-00576-3","volume":"15","author":"M Lasica","year":"2020","unstructured":"Lasica M, Tam CS. Management of ibrutinib toxicities: a practical guide. Curr Hematol Malig Rep. 2020;15(3):177\u201386. https:\/\/doi.org\/10.1007\/s11899-020-00576-3.","journal-title":"Curr Hematol Malig Rep"},{"issue":"4","key":"757_CR102","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1182\/blood-2017-08-764712","volume":"131","author":"JR Brown","year":"2018","unstructured":"Brown JR. How I treat CLL patients with ibrutinib. Blood. 2018;131(4):379\u201386. https:\/\/doi.org\/10.1182\/blood-2017-08-764712.","journal-title":"Blood"},{"issue":"2","key":"757_CR103","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1080\/14740338.2024.2339448","volume":"24","author":"X Li","year":"2025","unstructured":"Li X, Shang N, Yan Q, Yue X, Liu Y, Zheng X. Investigating bleeding adverse events associated with BTK inhibitors in the food and drug administration adverse event reporting system (FAERS). Expert Opin Drug Saf. 2025;24(2):183\u201392. https:\/\/doi.org\/10.1080\/14740338.2024.2339448.","journal-title":"Expert Opin Drug Saf"},{"key":"757_CR104","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-025-02529-3","author":"I Kre\u010dak","year":"2025","unstructured":"Kre\u010dak I, Kvinta B, Paladin M, et al. High lymphocyte count and bleeding risk in patients with chronic lymphocytic leukemia treated with Bruton\u2019s tyrosine kinase inhibitors. Wien Klin Wochenschr. 2025. https:\/\/doi.org\/10.1007\/s00508-025-02529-3.","journal-title":"Wien Klin Wochenschr"},{"issue":"10","key":"757_CR105","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","volume":"102","author":"JR Brown","year":"2017","unstructured":"Brown JR, Moslehi J, O\u2019Brien S, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017;102(10):1796\u2013805. https:\/\/doi.org\/10.3324\/haematol.2017.171041.","journal-title":"Haematologica"},{"issue":"5","key":"757_CR106","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1111\/bjh.15080","volume":"180","author":"JG Gribben","year":"2018","unstructured":"Gribben JG, Bosch F, Cymbalista F, et al. Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice. Br J Haematol. 2018;180(5):666\u201379. https:\/\/doi.org\/10.1111\/bjh.15080.","journal-title":"Br J Haematol"},{"issue":"4","key":"757_CR107","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jacasi.2022.02.001","volume":"2","author":"Y Okumura","year":"2022","unstructured":"Okumura Y. ABC pathway: a pivotal strategy for the integrated care management of atrial fibrillation. JACC Asia. 2022;2(4):430\u20132. https:\/\/doi.org\/10.1016\/j.jacasi.2022.02.001.","journal-title":"JACC Asia"},{"issue":"36","key":"757_CR108","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","volume":"45","author":"IC Van Gelder","year":"2024","unstructured":"Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314\u2013414. https:\/\/doi.org\/10.1093\/eurheartj\/ehae176.","journal-title":"Eur Heart J"},{"issue":"2","key":"757_CR109","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jaccao.2023.01.007","volume":"5","author":"T Lopez-Fernandez","year":"2023","unstructured":"Lopez-Fernandez T. CHA(2)DS(2)-VASc score in cardio-oncology: sharpening the rules. JACC CardioOncol. 2023;5(2):186\u20138. https:\/\/doi.org\/10.1016\/j.jaccao.2023.01.007.","journal-title":"JACC CardioOncol"},{"key":"757_CR110","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.amjcard.2025.04.025","volume":"249","author":"M Al Mouslmani","year":"2025","unstructured":"Al Mouslmani M, Alahmad MA, Akman Z, Rossi R, Rahman M, Nanna MG. CHA(2)DS(2)-VASc score in patients with atrial fibrillation and cancer: a US nationwide study. Am J Cardiol. 2025;249:59\u201364. https:\/\/doi.org\/10.1016\/j.amjcard.2025.04.025.","journal-title":"Am J Cardiol"},{"issue":"34","key":"757_CR111","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1093\/eurheartj\/ehae463","volume":"45","author":"M Dafaalla","year":"2024","unstructured":"Dafaalla M, Costa F, Kontopantelis E, et al. Bleeding risk prediction after acute myocardial infarction-integrating cancer data: the updated PRECISE-DAPT cancer score. Eur Heart J. 2024;45(34):3138\u201348. https:\/\/doi.org\/10.1093\/eurheartj\/ehae463.","journal-title":"Eur Heart J"},{"issue":"1","key":"757_CR112","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/jcpt.12355","volume":"41","author":"E Lambert Kuhn","year":"2016","unstructured":"Lambert Kuhn E, Leveque D, Lioure B, Gourieux B, Bilbault P. Adverse event potentially due to an interaction between ibrutinib and verapamil: a case report. J Clin Pharm Ther. 2016;41(1):104\u20135. https:\/\/doi.org\/10.1111\/jcpt.12355.","journal-title":"J Clin Pharm Ther"},{"issue":"11","key":"757_CR113","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.hrcr.2021.08.003","volume":"7","author":"R Kapoor","year":"2021","unstructured":"Kapoor R, Fazal M, Cheng P, Witteles R, Rhee JW, Baykaner T. Ibrutinib-associated atrial fibrillation treatment with catheter ablation. HeartRhythm Case Rep. 2021;7(11):713\u20136. https:\/\/doi.org\/10.1016\/j.hrcr.2021.08.003.","journal-title":"HeartRhythm Case Rep"},{"key":"757_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02413-5","author":"J Alexandre","year":"2024","unstructured":"Alexandre J, Font J, Angelique DS, et al. Is ibrutinib-related atrial fibrillation dose dependent? Insights from an individual case level analysis of the World Health Organization pharmacovigilance database. Leukemia. 2024. https:\/\/doi.org\/10.1038\/s41375-024-02413-5.","journal-title":"Leukemia"},{"issue":"2","key":"757_CR115","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euaf018","volume":"27","author":"L Shi","year":"2025","unstructured":"Shi L, Duan Y, Fang N, et al. Lactobacillus gasseri prevents ibrutinib-associated atrial fibrillation through butyrate. Europace. 2025;27(2): euaf018. https:\/\/doi.org\/10.1093\/europace\/euaf018.","journal-title":"Europace"},{"issue":"5","key":"757_CR116","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s10840-022-01400-z","volume":"66","author":"M Fazal","year":"2023","unstructured":"Fazal M, Wei C, Chuy KL, et al. Tyrosine kinase inhibitor-associated ventricular arrhythmias: a case series and review of literature. J Interv Card Electrophysiol. 2023;66(5):1165\u201375. https:\/\/doi.org\/10.1007\/s10840-022-01400-z.","journal-title":"J Interv Card Electrophysiol"},{"key":"757_CR117","doi-asserted-by":"publisher","first-page":"1513913","DOI":"10.3389\/fphar.2024.1513913","volume":"15","author":"Y Pan","year":"2024","unstructured":"Pan Y, Zhao Y, Ren H, et al. Epidemiology, clinical characteristics and potential mechanism of ibrutinib-induced ventricular arrhythmias. Front Pharmacol. 2024;15:1513913. https:\/\/doi.org\/10.3389\/fphar.2024.1513913.","journal-title":"Front Pharmacol"},{"issue":"40","key":"757_CR118","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","volume":"43","author":"K Zeppenfeld","year":"2022","unstructured":"Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40):3997\u20134126. https:\/\/doi.org\/10.1093\/eurheartj\/ehac262.","journal-title":"Eur Heart J"},{"issue":"1","key":"757_CR119","doi-asserted-by":"publisher","DOI":"10.1002\/cai2.151","volume":"4","author":"P Li","year":"2025","unstructured":"Li P, Liu D, Gao P, et al. Mitigating ibrutinib-induced ventricular arrhythmia and cardiac dysfunction with metformin. Cancer Innov. 2025;4(1): e151. https:\/\/doi.org\/10.1002\/cai2.151.","journal-title":"Cancer Innov"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00757-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-025-00757-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00757-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T14:31:43Z","timestamp":1776781903000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-025-00757-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":119,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["757"],"URL":"https:\/\/doi.org\/10.1007\/s40256-025-00757-6","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]},"assertion":[{"value":"27 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GBZ has consulted for Aleph, Amarin, Balmed, Cardionovum, Crannmedical, Endocore Lab, Eukon, Guidotti, Innovheart, Meditrial, Menarini, Microport, Opsens Medical, Terumo, and Translumina, outside the present work. PS has received consulting fees from Axis-TV, AstraZeneca, BMS, Les Laboratoires Servier, Novartis, Menarini, and Sanofi, outside the submitted work. LS, FR, EBO, GP, MG, SC, GS, BS, ER, AL, FV, IC, VV, SS, and MB have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"LS conceived the manuscript, drafted the initial version, and coordinated the responses to reviewers. FR and EB-O contributed to the manuscript drafting and literature review, alongside GP and MG. SC, PS, GS, BS, ER, AL, FV, GBZ, IC, VV, and SS provided critical internal review and supervision throughout the writing process. MB oversaw the project and provided final supervision and critical appraisal. All authors reviewed and approved the final version of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Data sharing is not applicable as no datasets were generated for this review article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}